Low-density-lipoprotein apheresis-mediated endothelial activation therapy to severe-peripheral artery disease study: Rationale and study design.

• 影响指数: 2.195
• 发表时间: Oct 2020
• 来源期刊: Ther Apher Dial
• DOI: 10.1111/1744-9987.13546
• PMID: 32524727
• 文章类型: Journal Article
• 中科院分区: Q4
• 方向: 医学
• 作者列表: Ueda E,Toya Y,Wakui H,Kawai Y,Azushima K,Fujita T,Saigusa Y,Yamanaka T,Yabuki Y,Mikami T,Goda M,Sugano T,Tamura K

关键词: dextran sulfate cellulose column; endothelial function; lipoprotein apheresis; normal cholesterol; peripheral arterial disease

Mesh: Aged; Blood Component Removal / methods; Cholesterol, LDL / blood; Endothelium, Vascular / physiopathology; Female; Humans; Male; Middle Aged; Peripheral Arterial Disease / blood physiopathology therapy

Abstract

A novel approach is required for standard therapy-resistant peripheral arterial disease (PAD). This is a single-center, single-arm, interventional study (LDL Apheresis-Mediated Endothelial Activation Therapy to Severe-Peripheral Artery Disease study), which aims to evaluate the efficacy and safety of lipoprotein apheresis (LA) with a dextran sulfate cellulose column in PAD with controlled serum cholesterol levels. The study participants have standard therapy-resistant PAD with controlled serum cholesterol levels. A total of 35 patients undergo 10 sessions of LA therapy. The ankle-brachial index and vascular quality of life questionnaire are assessed before and after the treatment period as primary outcomes. Registration of patients began in November 2015 and is planned to be concluded in October 2020.